TX-103

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameTX-103
Drug Alias NameTX-103TX103-CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocyte replacementsAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFuzhou Tcelltech Biological Science and Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTcelltech IncFuzhou Tcelltech Biological Science and Technology Co LtdTcelltech Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A